Mumbai, December 31, 2025: Jubilant Pharmova Limited (NSE: JUBLPHARMA | BSE: 530019) has informed stock exchanges that it has received an income tax demand order amounting to ₹22.10 crore for the financial year 2020. The company has stated that it is taking corrective and appellate steps and does not expect any material financial impact from the order.
Details of the Tax Demand
According to the disclosure, Jubilant Pharmova received an order dated December 27, 2025, from the Income Tax Department, DCIT/ACIT (Central), Moradabad. The order was received by the company on December 30, 2025, at 4:23 PM IST. The tax demand raised stands at ₹22.10 crore.The demand primarily arises from arithmetical errors and mistakes apparent from records, along with certain disallowances of expenses and deductions, and transfer pricing adjustments. The company has stated that these adjustments were made ignoring its submissions during the assessment process.
Company’s Response and Next Steps
Jubilant Pharmova has indicated that it is in the process of filing a rectification application with the assessing officer to address the errors identified in the order. In addition, the company may also appeal the assessment order before the Income Tax Appellate Tribunal, as required.The management has stated that it expects relief from the assessing or appellate authorities and has clarified that it does not anticipate any material financial implications arising from the demand.
Summary of Litigation Details
| Particulars | Details |
|---|---|
| Financial year involved | FY 2020 |
| Tax demand amount | ₹22.10 crore |
| Authority issuing order | Income Tax Department, DCIT/ACIT (Central), Moradabad |
| Nature of demand | Arithmetical errors, expense disallowances, deduction issues, transfer pricing adjustments |
| Company action | Rectification application and or appeal before ITAT |
| Financial impact outlook | No material impact expected |
About the Company
Jubilant Pharmova Limited is a diversified pharmaceutical company with operations spanning pharmaceuticals, contract research and development services, generics, and specialty businesses. The company is listed on both the National Stock Exchange of India and BSE.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.